Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545706 | 0.94 | KMT2A (0.49) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29362505 | 0.89 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL119779 | 0.89 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29503775 | 0.89 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL6647665 | 0.88 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL30809552 | 0.88 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL10205819 | 0.87 | KMT2A (0.58) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL12560390 | 0.86 | KMT2A (0.52) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL8687186 | 0.86 | KMT2A (0.52) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL1880388 | 0.86 | KMT2A (0.55) | KMT2AEPHX2CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374861-A1 | KIT FOR TUMOR IMAGING | THOMAS JEFFERSON UNIVERSITY | 2015-12-31 | — | — | US | disclosed |
| EP-2956157-A1 | KIT FOR TUMOR IMAGING | Thomas Jefferson University (US) | 2015-12-23 | — | — | EP | disclosed |
| WO-2014126902-A1 | KIT FOR TUMOR IMAGING | THOMAS JEFFERSON UNIVERSITY (US) | 2014-08-21 | — | — | WO | disclosed |
| WO-2004031220-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374861-A1 | KIT FOR TUMOR IMAGING | ARG1, TIE1, TYR | KMT2A 195/4885EPHX2 3912/4885CASP3 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.